Boston Scientific has agreed to acquire Penumbra in a transformative $14.5 billion all-cash transaction, marking one of the largest mergers in the medical technology sector. The deal expands Boston Scientific’s leadership in neurovascular interventions and strengthens its position in stroke care.
- Boston Scientific to acquire Penumbra in an all-cash deal valued at $14.5 billion
- Offer: $140 per share, representing a 25% premium over Penumbra’s 30-day VWAP
- Penumbra’s 2025 revenue: $1.1 billion, with 10% YoY growth
- Expected closing: second half of 2026, pending regulatory approvals
- Projected annual cost synergies: $200 million within three years
- Combined entity expected to generate over $20 billion in annual revenue
Boston Scientific Corp. has entered into a definitive agreement to acquire Penumbra Inc. in an all-cash transaction valued at $14.5 billion. The acquisition, structured as a cash offer of $140 per share, reflects a 25% premium over Penumbra’s 30-day volume-weighted average price. The deal is expected to close in the second half of 2026, subject to customary regulatory approvals and closing conditions. The transaction underscores Boston Scientific’s strategic push to deepen its presence in the neurovascular market, where Penumbra is a leader in stroke treatment technologies. Penumbra’s flagship products, including its neurothrombectomy systems and advanced clot retrieval devices, are widely used in emergency stroke interventions. The acquisition will integrate Penumbra’s innovation pipeline and clinical expertise into Boston Scientific’s existing cardiovascular and neuromodulation divisions. Financially, the $14.5 billion price tag represents a significant commitment by Boston Scientific to scale its high-growth specialty segments. Penumbra reported revenue of $1.1 billion in 2025, with a 10% year-over-year growth, driven by strong demand in the U.S. and international markets. The combined entity is projected to generate over $20 billion in annual revenue post-merger, with enhanced R&D capabilities and expanded commercial reach. The deal will impact stakeholders across the medical technology ecosystem, including investors, healthcare providers, and patients. Shareholders of Penumbra will benefit from the premium valuation, while Boston Scientific anticipates cost synergies of approximately $200 million annually within three years of closing. Regulatory scrutiny remains a key risk factor, particularly in the U.S. and European Union, where antitrust reviews are expected.